Targeson Receives Grant to Develop Ultrasound-Based Kidney Therapeutic
Charlottesville, VA – Feb 1, 2009 – Targeson announced today that it has been awarded a Phase I small business innovation research (SBIR) award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH). This project, to be led by Targeson Vice President for Research Dr. Joshua (Jack) Rychak, aims to develop an ultrasound-mediated therapy for delivery of therapeutics to the diabetic kidney. The project builds on Targeson’s proprietary targeted microbubble platform. Research will be performed in conjunction with Dr. Kumar Sharma, Director of Translational Research in Kidney Disease and Professor of Medicine at the University of California, San Diego.
About Targeson
Targeson, Inc., (www.targeson.com), develops, manufactures, and markets ultrasound imaging agents for preclinical functional and molecular imaging applications. The company’s contrast agent technologies enable researchers to quantify microvascular perfusion and characterize diseases at the molecular level using portable and cost-efficient ultrasound ultrasound imaging.